Nuvasive EBIT

The latest EBIT for NUVA is $80M as of June 2023. That compares with $57M in the prior-year period — up 41.4% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Nuvasive's historical trend and sector peers before judging valuation or financial health.

Over the past year, NUVA's EBIT moved from $57M to $80M — a 41.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nuvasive's operating scale or balance-sheet position.

Against Healthcare companies, NUVA currently prints $80M for EBIT, while the sector average sits near $110B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at Nuvasive's growth, margins, and balance sheet.

A EBIT figure of $80M for NUVA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting NUVA's EBIT ($80M), review year-over-year change from $57M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.